Bausch Health Companies (BHC) vs Harmony Biosciences (HRMY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Harmony Biosciences (HRMY) has outperformed Bausch Health Companies (BHC) over the past year, gaining 49.1% versus a loss of 4.7%. Over five years, HRMY leads with a +0.5% price change compared with -78.8% for BHC. Harmony Biosciences is the larger company by market cap ($2.34 billion vs $2.28 billion), about 1.0 times the size.
On valuation, Bausch Health Companies trades at a lower forward P/E (1.5x vs 5.7x for Harmony Biosciences). Harmony Biosciences converts more of its revenue into profit, with a net margin of 18.3% versus 1.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BHC | HRMY |
|---|---|---|
| Share price | $6.09 | $40.18 |
| Market cap | $2.28B | $2.34B |
| 1-day change | +0.75% | +1.46% |
| YTD return | -13.09% | +5.83% |
| 1-year return | -4.73% | +49.10% |
| 5-year return | -78.80% | +0.51% |
| P/E ratio (TTM) | — | 12.96 |
| Forward P/E | 1.45 | 5.74 |
| EPS (TTM) | $-2.95 | $3.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $10.27B | $868.45M |
| Revenue growth (YoY) | +6.66% | +21.51% |
| Net income (latest FY) | $157.00M | $158.69M |
| Gross margin | — | 77.16% |
| Operating margin | 17.66% | 24.00% |
| Net margin | 1.53% | 18.27% |
| 52-week high | $8.00 | $43.49 |
| 52-week low | $4.33 | $25.52 |
| Distance from 52-week high | -23.94% | -7.61% |
| Analyst consensus | hold | buy |
| Avg. price target upside | +23.25% | +18.57% |
| Average volume | 3.24M | 892.55K |
| Shares outstanding | 373.99M | 58.24M |
| Employees | 20,300 | 293 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HRMY has outperformed BHC by 53.8 percentage points over the past year.
- Harmony Biosciences is more profitable, keeping 18.3 cents of every revenue dollar as net income versus 1.5 cents for Bausch Health Companies.
- Harmony Biosciences grew revenue faster in its latest fiscal year (+21.51% vs +6.66%).
About Bausch Health Companies
BHC stock →Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company.
Health Care · Biotechnology: Pharmaceutical Preparations · 20,300 employees
About Harmony Biosciences
HRMY stock →Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
Health Care · Biotechnology: Pharmaceutical Preparations · 293 employees
BHC vs HRMY FAQ
Which is bigger, Bausch Health Companies or Harmony Biosciences?
Harmony Biosciences (HRMY) is larger, with a market capitalization of $2.34B compared with $2.28B for Bausch Health Companies (BHC).
Which stock has performed better over the past year, BHC or HRMY?
HRMY returned +49.10% over the past 12 months, compared with -4.73% for BHC (price return, excluding dividends). Past performance does not predict future results.
Are Bausch Health Companies and Harmony Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.